Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics Inc (NQ: HOWL )

2.750 +0.550 (+25.00%)
Streaming Delayed Price Updated: 3:21 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 449,675
Open 2.240
Bid (Size) 2.740 (7)
Ask (Size) 2.760 (6)
Prev. Close 2.200
Today's Range 2.240 - 2.770
52wk Range 1.573 - 8.194
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where Werewolf Therapeutics Stands With Analysts
Via Benzinga
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
From Werewolf Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-40.73%
-40.73%
1 Month
-15.38%
-15.38%
3 Month
-48.02%
-48.02%
6 Month
-45.87%
-45.87%
1 Year
-14.60%
-14.60%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
Via Benzinga
Recap: Werewolf Therapeutics Q4 Earnings
Via Benzinga
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Fall Off A Cliff This Month
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.